Profile data is unavailable for this security.
About the company
Sareum Holdings plc is a United Kingdom-based biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company's internal programs focus on distinct dual tyrosine kinase 2 (TYK2)/ Janus kinase 1 (JAK1) inhibitors, which are progressing through preclinical development as therapies for autoimmune diseases and cancers. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with an initial focus on psoriasis. It is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. The Company also has an interest in SRA737, an orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of important cell cycle checkpoints and a central mediator of the DNA damage response (DDR) network.
- Revenue in GBP (TTM)0.00
- Net income in GBP-4.26m
- Incorporated2004
- Employees5.00
- LocationSareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
- Phone+44 122 349 7700
- Fax+44 122 349 7701
- Websitehttps://sareum.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Destiny Pharma PLC | 0.00 | -5.97m | 15.96m | 20.00 | -- | 1.34 | -- | -- | -0.0759 | -0.0759 | 0.00 | 0.1251 | 0.00 | -- | -- | 0.00 | -48.68 | -47.98 | -52.87 | -52.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.80 | -- | -45.97 | -- |
| OptiBiotix Health PLC | 689.10k | -13.17m | 17.38m | 3.00 | -- | 1.73 | -- | 25.23 | -0.1489 | -0.1489 | 0.0078 | 0.1029 | 0.0426 | 2.28 | 1.25 | 229,700.00 | -81.35 | 17.83 | -83.43 | 18.66 | 49.31 | 54.87 | -1,911.88 | 190.54 | 3.24 | -0.089 | 0.00 | -- | -79.35 | 19.05 | -58.68 | 6.28 | 30.03 | -- |
| Oncimmune Holdings PLC | 1.15m | -6.15m | 17.42m | 56.00 | -- | 26.52 | -- | 15.12 | -0.0859 | 0.0507 | 0.0159 | 0.0089 | 0.1239 | 1.08 | 0.5941 | -- | -66.15 | -- | -131.46 | -- | 68.75 | -- | -533.94 | -- | 3.75 | -1.96 | 0.8897 | -- | -- | -- | -- | -- | -- | -- |
| Verici DX PLC | 15.18k | -8.96m | 17.51m | 14.00 | -- | 2.30 | -- | 1,153.26 | -0.0526 | -0.0526 | 0.00009 | 0.0314 | 0.0013 | -- | 0.1152 | 1,012.28 | -77.76 | -- | -92.28 | -- | 84.21 | -- | -59,015.79 | -- | -- | -- | 0.0232 | -- | -- | -- | -36.94 | -- | -- | -- |
| LungLife AI Inc | 36.76k | -4.33m | 18.32m | 19.00 | -- | 1.20 | -- | 498.31 | -0.1697 | -0.1697 | 0.0014 | 0.2481 | 0.0038 | -- | 0.1474 | 1,934.83 | -44.11 | -- | -50.09 | -- | 100.00 | -- | -11,767.39 | -- | -- | -- | 0.0419 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Skinbiotherapeutics PLC | 161.65k | -2.88m | 18.54m | 11.00 | -- | 4.82 | -- | 114.66 | -0.0165 | -0.0165 | 0.0009 | 0.0192 | 0.0522 | 0.8871 | 0.4181 | 14,695.45 | -93.07 | -52.07 | -115.26 | -57.33 | 62.90 | -- | -1,784.70 | -4,694.37 | 6.48 | -379.78 | 0.0259 | -- | 76.65 | -- | -1.52 | -- | 18.00 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -6.69m | 21.27m | 17.00 | -- | 6.61 | -- | -- | -0.0061 | -0.0061 | 0.00 | 0.0024 | 0.00 | -- | -- | 0.00 | -101.47 | -82.19 | -112.85 | -95.97 | -- | -- | -- | -- | -- | -28.03 | 0.5144 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
| Oxford Biodynamics PLC | 510.00k | -10.83m | 25.57m | 45.00 | -- | 2.74 | -- | 50.14 | -0.0729 | -0.0729 | 0.0035 | 0.0299 | 0.0371 | 0.7987 | 0.332 | 11,333.33 | -78.82 | -39.72 | -105.32 | -45.52 | 52.16 | -- | -2,122.75 | -1,324.62 | 1.72 | -7.50 | 0.5154 | -- | 231.17 | -15.53 | -61.34 | -- | -1.60 | -- |
| Sareum Holdings Plc | 0.00 | -4.26m | 27.45m | 5.00 | -- | 44.23 | -- | -- | -0.0614 | -0.0614 | 0.00 | 0.0059 | 0.00 | -- | -- | 0.00 | -160.20 | -71.41 | -195.05 | -81.48 | -- | -- | -- | -19,709.24 | -- | -6.61 | 0.00 | -- | -- | -- | -46.96 | -- | -- | -- |
| Science in Sport PLC | 65.93m | -7.07m | 28.71m | 158.00 | -- | 0.7213 | -- | 0.4354 | -0.0464 | -0.0464 | 0.4239 | 0.2184 | 0.8479 | 4.20 | 3.83 | 417,278.50 | -9.09 | -9.69 | -13.75 | -11.97 | 41.88 | 47.09 | -10.72 | -11.94 | 0.6921 | -2.31 | 0.2825 | -- | 1.97 | 32.50 | -96.47 | -- | 49.81 | -- |
| CRUSHMETRIC Group Ltd | 397.92k | -878.53k | 29.94m | 20.00 | -- | 1.17 | -- | 75.23 | -0.0072 | -0.0072 | 0.0028 | 0.1061 | 0.0255 | 7.14 | 2.64 | 19,895.79 | -5.72 | -40.65 | -8.35 | -- | 34.66 | 37.39 | -224.56 | -140.54 | 0.072 | -14.42 | 0.0558 | -- | 119.19 | -1.40 | -7.26 | -- | 12.11 | -- |
| Redx Pharma PLC | 4.20m | -33.16m | 38.90m | 101.00 | -- | 9.98 | -- | 9.26 | -0.099 | -0.099 | 0.0126 | 0.01 | 0.0954 | -- | 135.55 | 41,603.96 | -75.26 | -52.99 | -166.19 | -88.10 | -- | -- | -789.05 | -206.66 | -- | -- | 0.8405 | -- | -77.52 | 100.71 | -84.15 | -- | 8.12 | -- |
Data as of Apr 26 2024. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX
14.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Asset Management Ltd.as of 01 Apr 2024 | 4.57m | 6.36% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Apr 2024 | 3.29m | 4.58% |
| Jarvis Investment Management Ltd.as of 01 Apr 2024 | 1.20m | 1.67% |
| IG Markets Ltd.as of 01 Apr 2024 | 420.00k | 0.59% |
| Rowan Dartington & Co. Ltd. (Broker)as of 01 Apr 2024 | 172.00k | 0.24% |
| Evelyn Partners Investment Management Services Ltd.as of 01 Apr 2024 | 117.00k | 0.16% |
| KW Investment Management Ltd.as of 01 Apr 2024 | 108.00k | 0.15% |
| iDealing.com Ltd.as of 01 Apr 2024 | 92.00k | 0.13% |
| Eurizon Capital SGR SpAas of 01 Apr 2024 | 91.00k | 0.13% |
| J. M. Finn & Co. Ltd.as of 01 Apr 2024 | 89.00k | 0.12% |
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
